small hepatocellular carcinoma [J]. Int J Oncol, 2000,17(2):237243.
[18] 蔡阳,吴志全,樊嘉,等.基质金属蛋白酶9与肝细胞癌侵袭转移性的关系[J].外科理论与实践，2000,5(4):245247.
[19] 胡劲松,翟为溶,张月娥,等.基质金属蛋白酶及组织抑制因子在肝癌中的表达及与预后的关系[J].中华消化杂志，2001,21(8):461464.
[20] KUYVENHOVEN J P, van HOEK B, BLOM E, et al. Assessment of the clinical significance of serum matrix metalloproteinases MMP2 and MMP9 in patients with various chronic liver diseases and hepatocellular carcinoma [J]. Thromb Haemostasis, 2003,89(4):718725.
[21] 刘玮,冯浩,刘瑞文,等.肝癌中COX2蛋白与MMP2蛋白的表达及其相关性研究[J].交通医学,2008,22(6):639646.
[22] 陈连周,王东,谢巧庆,等.基质金属蛋白酶9及其抑制因子与肝癌侵袭转移的关系[J].中国热带医学,2008，8(11):19141916.
[23] JIANG Y, GOLDBERG I D, SHI Y E. Complex roles of tissue inhibitors of metalloproteinases in cancer[J]. Oncogene, 2002,21(14):22452252.
[24] MCKENNA G J, CHEN Y, SMITH R M, et al. A role for matrix metalloproteinases and tumor host interaction in hepatocellular carcinomas [J]. Am J Surg, 2002,183(5):588594.
[25] CHENG J C H, CHOU C H, KUO M L, et al. Radiationenhanced hepatocellular carcinoma cell invasion with MMP9 expression through PI3K/Akt/NFкB signal transduction pathway [J]. Oncogene, 2006,25:70097018.
[26] 毕明俊,李琴.射频消融术对肝细胞肝癌患者血浆基质金属蛋白酶1，7，9，13的影响[J].实用全科医学,2008,1,6(1):4647.
[27] ZHANG Q, CHEN X G, ZHOU J, et al. CD147, MMP2, MMP9 and MVDCD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients[J]. Cancer Biol Ther, 2006,5(7):808814.
[28] WOJTOWICIPRAGA S. Clinical potential of matrix metalloproteinase inhibitors[J]. Drug R D, 1999,1(2):117129.
[29] LAKKA S S, RAJAN M, CONDI C, et al. Adenovirusmediated expression of antisense MMP9 in glioma cells inhibits tumor growth and invasion [J]. Oncogene, 2002,21(5):80118019.
[30] 张弘，韩喜春，王悦书，等.基质金属蛋白酶抑制剂3基因转染抗人肝癌细胞系侵袭与转移的研究[J].中华普通外科杂志，2004，19(6)：379380.
[31] BAKER E A, STEPHENSON T J, REED M W R, et
上一页 [1] [2] [3] [4] [5] [6] [7] 下一页
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文